Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy
β Scribed by F.K. Zhang; Y. Zhang; J.Y. Zhang; J.D. Jia; B.E. Wang
- Book ID
- 110904347
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 107 KB
- Volume
- 11
- Category
- Article
- ISSN
- 1398-2273
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The characteristics of hepatitis B virus (HBV) in vaccinated children who acquire de novo HBV infections after orthotopic liver transplantation (OLT) remain largely unknown. The aim of this study was to explore HBV mutants in pediatric OLT recipients with de novo HBV infections. In all, 50 recipient
The aim of this study is to determine the origin, clinical outcome, allograft histological characteristics, and virological outcome of de novo hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). We studied 136 hepatitis B surface antigen (HBsAg)-negative liver transplant
New-onset hepatitis B (de novo B) after liver transplantation (OLTX) is an emerging concern. The goals of our study were to determine the incidence and pattern of this infection, to attempt determination of risk factors and the role of immunosuppression, and to review its morbidity/mortality. Over a
Hepatitis B after liver transplantation is often fatal, and no proven medical therapy exists for this condition. We chose to study the potential efficacy of lamivudine therapy for patients with chronic hepatitis B after liver transplantation. Fifty-two patients with chronic hepatitis B after liver t